Therapeutic Autologous Dendritic Cells
Therapeutic Autologous Dendritic Cells is a biological therapy with 35 clinical trials. Currently 1 active trials ongoing. Historical success rate of 71.4%.
Success Metrics
Based on 20 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
14
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
69.0%
20 of 29 finished
31.0%
9 ended early
1
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Clinical Trials (35)
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
Vaccine Therapy in Treating Patients With Malignant Glioma
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
p53 Vaccine for Ovarian Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
Biological Therapy in Treating Patients With Advanced Cancer
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 35